Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Clalit Health Services

Status and phase: Completed; Phase 3

Conditions: Parkinson Disease

Treatments: Drug: Opicapone

Study type: Interventional

Funder types: Other

Identifiers

NCT01851850

BIA-91067

Details and patient eligibility

About

The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.

Enrollment: 1 patient

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• clinical diagnosis with PD
• subjects who are willing to participate in the trial.
• subjects who participated in the BIA 9-1067-302 clinical trial.

Exclusion criteria

• subjects who didn't take part at the BIA 9-1067-302 clinical trial.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Drug

Experimental group

Treatment:

Drug: Opicapone